Blood:利妥昔单抗联合来那度胺作为一线疗法用于滤泡性淋巴瘤患者的疗效和安全性

2019-05-18 MedSci MedSci原创

Emanuele Zucca等人开展2期SAKK35/10试验(NCT01307605)评估利妥昔单抗对比利妥昔单抗联合来那度胺治疗未治疗过的需要系统治疗的滤泡性淋巴瘤患者的疗效。受试患者被随机分至单药组(利妥昔单抗 375mg/m2 IV,第1天,1-4周,有反应的患者于12-15周时重复给药)或联合组(利妥昔单抗[用药方案与单药组一样]+来那度胺 15mg/日 PO,连续用18周)。主要结点是

中心点:

与单用利妥昔单抗相比,短疗程的利妥昔单抗联合来那度胺可显著提高未治疗过的滤泡性淋巴瘤患者的缓解率和无进展存活期。

摘要:

Emanuele Zucca等人开展2期SAKK35/10试验(NCT01307605)评估利妥昔单抗对比利妥昔单抗联合来那度胺治疗未治疗过的需要系统治疗的滤泡性淋巴瘤患者的疗效。受试患者被随机分至单药组(利妥昔单抗 375mg/m2 IV,第1天,1-4周,有反应的患者于12-15周时重复给药)或联合组(利妥昔单抗[用药方案与单药组一样]+来那度胺 15mg/日 PO,连续用18周)。主要结点是6个月时的完全缓解(CR/CRu)率。

总体上,共招募了154位患者,两组各77位,每组低FLIPI风险患者占47%。6个月时,联合组的CR/CRu率显著高于单药组(36%,95% CI:26-48% vs 25%,16-36%),且经过CT扫描验证(61%,49-72% vs 36%,26-48%)。

中位随访4年后,与单药组相比,联合组的30个月CR/CRu率更高,无进展存活期(PFS)和二次治疗的间隔时间(TTNT)均更长。但两组的总体存活率(OS)相似(≥90%)。

3级及以上的毒性反应在联合组更常见(56% vs 22%),主要是中性粒细胞减少(23% vs 7%)。

综上所述,利妥昔单抗治疗再加上来那度胺可显著提高CR/CRu率、PFS和TTNT,只是副反应更多,但尚在可控范围。两组超高的存活率提示无化疗策略值得进一步探索。

原始出处:

Emanuele Zucca,et al. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood 2019 :blood-2018-10-879643; doi: https://doi.org/10.1182/blood-2018-10-879643

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1720902, encodeId=9f4a1e2090221, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Tue Apr 28 11:22:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660465, encodeId=aca7166046586, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32285, encryptionId=c0de32285a1, topicName=利妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a58d25117340, createdName=花花1374, createdTime=Mon Jul 08 15:22:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278794, encodeId=40ca12e8794f5, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66587, encryptionId=5bd36658e94, topicName=滤泡性淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Mon May 20 06:22:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366451, encodeId=c1fb3664517f, content=可以PDF版本吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db245098258, createdName=145eac9bm56暂无昵称, createdTime=Sun May 19 16:10:55 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366413, encodeId=b01436641313, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat May 18 23:37:44 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032162, encodeId=2d23103216266, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat May 18 18:22:00 CST 2019, time=2019-05-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1720902, encodeId=9f4a1e2090221, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Tue Apr 28 11:22:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660465, encodeId=aca7166046586, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32285, encryptionId=c0de32285a1, topicName=利妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a58d25117340, createdName=花花1374, createdTime=Mon Jul 08 15:22:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278794, encodeId=40ca12e8794f5, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66587, encryptionId=5bd36658e94, topicName=滤泡性淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Mon May 20 06:22:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366451, encodeId=c1fb3664517f, content=可以PDF版本吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db245098258, createdName=145eac9bm56暂无昵称, createdTime=Sun May 19 16:10:55 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366413, encodeId=b01436641313, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat May 18 23:37:44 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032162, encodeId=2d23103216266, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat May 18 18:22:00 CST 2019, time=2019-05-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1720902, encodeId=9f4a1e2090221, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Tue Apr 28 11:22:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660465, encodeId=aca7166046586, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32285, encryptionId=c0de32285a1, topicName=利妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a58d25117340, createdName=花花1374, createdTime=Mon Jul 08 15:22:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278794, encodeId=40ca12e8794f5, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66587, encryptionId=5bd36658e94, topicName=滤泡性淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Mon May 20 06:22:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366451, encodeId=c1fb3664517f, content=可以PDF版本吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db245098258, createdName=145eac9bm56暂无昵称, createdTime=Sun May 19 16:10:55 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366413, encodeId=b01436641313, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat May 18 23:37:44 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032162, encodeId=2d23103216266, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat May 18 18:22:00 CST 2019, time=2019-05-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1720902, encodeId=9f4a1e2090221, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Tue Apr 28 11:22:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660465, encodeId=aca7166046586, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32285, encryptionId=c0de32285a1, topicName=利妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a58d25117340, createdName=花花1374, createdTime=Mon Jul 08 15:22:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278794, encodeId=40ca12e8794f5, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66587, encryptionId=5bd36658e94, topicName=滤泡性淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Mon May 20 06:22:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366451, encodeId=c1fb3664517f, content=可以PDF版本吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db245098258, createdName=145eac9bm56暂无昵称, createdTime=Sun May 19 16:10:55 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366413, encodeId=b01436641313, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat May 18 23:37:44 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032162, encodeId=2d23103216266, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat May 18 18:22:00 CST 2019, time=2019-05-18, status=1, ipAttribution=)]
    2019-05-19 145eac9bm56暂无昵称

    可以PDF版本吗

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1720902, encodeId=9f4a1e2090221, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Tue Apr 28 11:22:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660465, encodeId=aca7166046586, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32285, encryptionId=c0de32285a1, topicName=利妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a58d25117340, createdName=花花1374, createdTime=Mon Jul 08 15:22:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278794, encodeId=40ca12e8794f5, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66587, encryptionId=5bd36658e94, topicName=滤泡性淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Mon May 20 06:22:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366451, encodeId=c1fb3664517f, content=可以PDF版本吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db245098258, createdName=145eac9bm56暂无昵称, createdTime=Sun May 19 16:10:55 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366413, encodeId=b01436641313, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat May 18 23:37:44 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032162, encodeId=2d23103216266, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat May 18 18:22:00 CST 2019, time=2019-05-18, status=1, ipAttribution=)]
    2019-05-18 清风拂面

    谢谢分享学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1720902, encodeId=9f4a1e2090221, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Tue Apr 28 11:22:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660465, encodeId=aca7166046586, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32285, encryptionId=c0de32285a1, topicName=利妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a58d25117340, createdName=花花1374, createdTime=Mon Jul 08 15:22:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278794, encodeId=40ca12e8794f5, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66587, encryptionId=5bd36658e94, topicName=滤泡性淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Mon May 20 06:22:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366451, encodeId=c1fb3664517f, content=可以PDF版本吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db245098258, createdName=145eac9bm56暂无昵称, createdTime=Sun May 19 16:10:55 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366413, encodeId=b01436641313, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat May 18 23:37:44 CST 2019, time=2019-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032162, encodeId=2d23103216266, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat May 18 18:22:00 CST 2019, time=2019-05-18, status=1, ipAttribution=)]
    2019-05-18 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

CLIN CANCER RES:Alisertib联合利妥昔单抗或利妥昔单抗/长春新碱治疗B细胞淋巴瘤

alisertib在B细胞非霍奇金淋巴瘤(B-NHL)中具有单药临床活性,与长春新碱/利妥昔单抗联合具有临床前协同作用。CLIN CANCER RES近期发表了一篇文章,研究alisertib联合使用利妥昔单抗±长春新碱治疗复发/难治性侵袭性B-NHL患者的安全性和推荐II期剂量(RP2D)。

AZ和Forty Seven正在临床测试淋巴瘤的三重免疫疗法组合

Forty Seven的CD47抗体5F9将与利妥昔单抗和Calquence(acalabrutinib)联合,用于进一步优化对侵袭性非霍奇金淋巴瘤(NHL)患者的治疗。Acalabrutinib是选择性的第二代BTK抑制剂,抑制B细胞表面原抗体信号通路的激活。

Ann Rheum Dis:当代实践中使用利妥昔单抗治疗系统性硬化症的结局

在这个大型SSc队列中,使用利妥昔单抗与良好的安全性相关。

Ann Rheum Dis:阿巴西普、利妥昔单抗和托珠单抗治疗类风湿性关节炎的严重感染风险

对于开始阿巴西普、利妥昔单抗或托珠单抗治疗的患者,基线特征存在差异。观察到药物间SI的发病率存在数值差异。

BMJ:利妥昔单抗、阿巴西普和托利珠单抗治疗类风湿关节炎疗效差异研究

研究认为,利妥昔单抗和托利珠单抗对难治性类风湿关节炎患者的治疗效果优于阿巴西普

国产生物类似药利妥昔单抗获批上市!

2月22日,上海复宏汉霖生物制药有限公司研制的利妥昔单抗注射液(商品名:汉利康;产品代号:HLX01)获得国家药品监督管理局批准,成为了国内获批的首个生物类似药。该药获批了原研利妥昔单抗在中国的所有适应证[1],包括:1)复发或耐药的滤泡性中央型淋巴瘤;2)先前未经治疗的CD20阳性III-IV期滤泡性非霍奇金淋巴瘤;3)CD20阳性弥漫大B细胞淋巴瘤(DLBCL)的治疗。淋巴瘤按病理分为霍奇金淋